Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
Go back to Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition| Harmony Metals, Inc. Common (NASDAQ: HRMY) | Delayed: 42.10 +0.03 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.07 | 52 Week High | $1.35 | |||
| Open | $42.01 | 52 Week Low | $0.10 | |||
| Day High | $42.41 | P/E | N/A | |||
| Day Low | $41.51 | EPS | $0.00 | |||
| Volume | 410,965 | |||||
